Loading...

ADC Therapeutics SA (NYSE:ADCT)

9.08 USD -1.11 USD ( -10.89% )
Watchlist Manager
ADC Therapeutics SA
NYSE:ADCT
Watchlist

Intrinsic Value

ADCT's intrinsic value estimate is unreliable because it is based only on its relative value.

The intrinsic value of one ADCT stock under the Base Case scenario is 16.69 USD. Compared to the current market price of 9.08 USD, ADC Therapeutics SA is Undervalued by 46%.

The Intrinsic Value is calculated as the average of the two valuation methods:

ADCT Intrinsic Value
Base Case
16.69 USD
Undervaluation 46%
Intrinsic Value
Price
A
Worst Case
Base Case
Best Case

Fundamental Analysis

ADCT Profitability Score
Profitability Due Diligence

ADC Therapeutics SA's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
29/100
Profitability
Score

ADC Therapeutics SA's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

ADCT Solvency Score
Solvency Due Diligence

ADC Therapeutics SA's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Low Interest Coverage
Low Altman Z-Score
High D/E
Long-Term Liabilities
34/100
Solvency
Score

ADC Therapeutics SA's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Wall Street
Price Targets

ADCT Price Targets
Price Targets made by Wall Street

Wall Street analysts forecast ADCT stock price to rise over the next 12 months.

12-month price targets for ADCT stock made by Wall Street professionals. The average price target is 26.52 USD with a low forecast of 15.15 USD and a high forecast of 46.2 USD.

Lowest
Price Target
15.15 USD
67% Upside
Average
Price Target
26.52 USD
192% Upside
Highest
Price Target
46.2 USD
409% Upside
View Analyst Estimates
View Analyst Estimates

Insider Trading

ADCT Insider Trading
Buy and sell transactions by insiders

There is no information about any insider activity
Why is insider trading important?

Competitors

Competitors Valuation
ADC Therapeutics SA Competitors

Shareholder Return

ADCT Price
ADC Therapeutics SA

1M 1M
+17%
6M 6M
-40%
1Y 1Y
-66%
3Y 3Y
-69%
5Y 5Y
-69%
Annual Price Range
9.08
52w Low
5.96
52w High
31.51
Price Metrics
Average Annual Return 8.67%
Standard Deviation of Annual Returns
N/A
Max Drawdown -88%

Company Profile

ADC Therapeutics SA

Country

Switzerland

Industry

Biotechnology

Market Cap

697M USD

Dividend Yield

0%

Description

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

Contact

VAUD
Epalinges
Biopole, route de la Corniche 3B
+41216530200.0
https://adctherapeutics.com/

IPO

-

Employees

312

Officers

CEO & Director
Dr. Ameet Mallik M.B.A., M.S.
Vice Chairman, Exec. VP & Gen. Counsel
Mr. Michael Forer L.L.B.
Co-Founder & Non-Exec. Director
Dr. Christopher J. Martin DPHIL, Ph.D.
Chief Financial Officer
Ms. Jennifer Creel
Investor Relations Officer
Amanda Hamilton
Chief Compliance Officer
Ms. Susan Romanus
Show More
Sr. VP & Chief HR Officer
Ms. Kimberly Pope
Sr. VP of R&D
Dr. Patrick van Berkel
Head of Chemistry Manufacturing & Control and VP
Dr. Michael Mulkerrin
Chief Commercial Officer & Sr. VP
Ms. Jennifer L. Herron
Show Less

See Also

Similar Stocks

ADCT Stock FAQ

What is the Intrinsic Value of one ADCT stock?

The intrinsic value of one ADCT stock under the Base Case scenario is 16.69 USD.

Is ADCT stock undervalued or overvalued?

Compared to the current market price of 9.08 USD, ADC Therapeutics SA is Undervalued by 46%.